Calidi Biotherapeutics ( (CLDI) ) has shared an announcement.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Calidi Biotherapeutics, a biotechnology company specializing in targeted antitumor therapies, has been notified by the NYSE that its warrants, trading under CLDI WS, will be delisted due to low trading prices. However, trading of Calidi’s common stock, CLDI, remains unaffected. The company is exploring options to appeal the decision. Calidi continues its focus on developing innovative cancer treatments through its stem cell-based platforms.
Find detailed analytics on CLDI stock on TipRanks’ Stock Analysis page.
